| Literature DB >> 19772618 |
Kavitha Sivasubramaiyan1, Swapnil Totey, Vijay Bhat, Satish M Totey, Kaushik Deb.
Abstract
Trophoblast differentiation and formation of the placenta are important events linked to post-implantation embryonic development. Models mimicking the biology of trophoblast differentiation in a post-implantation maternal microenvironment are needed for understanding disorders like placental-ischemia or for applications in drug-screening, and would help in overcoming the ethical impasse on using human embryos for such research. Here we attempt to create such a model by using embryoid bodies (EBs) and a biomimetic platform composed of a bilayer of fibronectin and gelatin on top of low-melting agarose. Using this model we test the hypothesis that cystic-EBs (day 30) that resemble blastocysts morphologically, are better sources as compared to noncytic EBs (day 10), for functional trophoblast differentiation; and that the Rho kinases inhibitor Y27632 can enhance this differentiation. Non/cytic EBs with/out Y27632 were grown on this platform for 28 days, and screened from secretion and expression of trophoblast and other lineage markers using ECLIA, RT-PCR, and Immunofluorescence. All EBs attached on this surface and rapidly proliferated into hCG and progesterone (P2) secreting functional trophoblast cells. However, the cells derived from cytic-EBs and cytic-EBs+ Y27632 showed the maximum secretion of these hormones and expressed IGF2, supporting our hypothesis. Also Y27632 reduced extraembryonic endoderm and trophoblast lineage differentiation from early noncystic-EBs, whereas, it specifically enhanced the induction of trophoblast and multinucleated syncitiotrophoblast differentiation from late cystic-EBs. In vivo trophoblast differentiation can be replicated in fibronectin based biomaterials, using cytic-EBs and by maneuvering the Rho-ROCK pathways. Response of EBs to a compound may vary temporally, and determination of their right stage is crucial for applications in directed-differentiation or drug-screening.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19772618 PMCID: PMC2754421 DOI: 10.1186/1423-0127-16-88
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
List of genes and RT-PCR primers used
| Gene | Sequence | Annealing Temperature (°C) | Product Size(bp) |
|---|---|---|---|
| Oct 4 | CGACCATCTGCCGCTTTGAG | 57 | 572 |
| Nanog | CCTCCTCCATGGATCTGCTTATTCA | 57 | 262 |
| GAPDH | GGGCGCCTGGTCACCAGGGCTG | 60 | 531 |
| βIIITubulin | CTTGGGGCCCTGGGCCTCCGA | 60 | 174 |
| GATA4 | TCCAAACCAGAAAACGGAAG | 60 | 187 |
| Brachury | ACCCAGTTCATAGCGGTGAC | 60 | 216 |
| BMP2 | TGTATCGCAGGCACTCAGGTCAG | 60 | 328 |
| GATA2 | TGACTTCTCCTGCATGCACT | 60 | 244 |
| HAND1 | TGCCTCAGAAAGAGAACCAG | 60 | 274 |
| BMP4 | GTCCTGCTAGGAGGCGCGAG | 60 | 339 |
| βhCG | GCTACTGCCCCACCATGACC | 55 | 95 |
| GCM1 | CGGAAACGCTGTCCCAACT | 57 | 235 |
| IGF2 | CAATGGGGAAGTCGATGCTG | 61 | 421 |
| FGFR1 | GGACTCTCCCATCACTCTGCAT | 56 | 109 |
Figure 1Trophoblast differentiation from embryoid bodies on the biomimetic platform. Panel (a) shows a non-cystic early EB. Panel (b) shows a late cytic EB with clear fluid filled cavity (red arrow) and a small mass of cells similar to inner cell mass (ICM) of an embryos (green arrowhead) pushed towards the top. Panel (c) shows a cystic EB outgrowing on the biomimetic platform on day 16. Panels (d) and (e) immunolocalization of trophoblast markers cytokeratin 8/Troma1 (red) and SSEA1 (green) in cytic EB outgrowths at early day 8. Blue (DAPI stain) represent the nuclei. This shows the evidences for the first signs for clear and distinct trophoblast cell differentiation from cystic EBs as early as day 8.
Figure 2Secretion of trophoblast and lineage markers. Graphs (a), (b) and (c) indicates secretion of hCG, progesterone (P2) and AFP from control and Y27632 treated outgrowth cultures from non-cystic early day 10 EBs. Graphs (d), (e) and (f) indicates secretion of hCG, progesterone (P2) and AFP from control and Y27632 treated outgrowth cultures from cystic late day 30 EBs. The values are represented as mean ± SD. Level of secretion in the treated cultures are marked by (*) and (**) to indicate significant (P < 0.05) and highly significant (P < 0.005) differences as compared to the control.
Figure 3Semiquantitative RT-PCR comparing the level of expression of AFP and IGF2 mRNA in control and Y27632 treated cytic EB cultures on day 16. The expression of AFP was seen to be stronger in the control (very faint band) as compared to treated cultures. However, expression of IGF2 a characteristic of trophoblast cells was seen to be stronger in the treated as compared to the control (faint band). The expression of β-actin was similar in both control and treated samples.